BioXcel Therapeutics is trading 5.5% up at $0.84 after positive late-stage data for its at-home agitation treatment strengthened confidence in the company’s pipeline.
- An August 21, 2026 deadline requires securing lender-approved financing or repaying obligations; reported cash is sufficient to fund operations only through August.
- Biotech-sector strength adds support, with XBI up 2.02%; the primary catalyst is company-specific.